HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Sept. 11, 2020 (HealthDay News) -- Pneumothorax is being reported as a complication of COVID-19, and has higher incidence among men and lower survival among older patients, according to a study published online Sept. 9 in the European Respiratory Journal.
Anthony W. Martinelli, Ph.D., from Addenbrooke's Hospital in Cambridge, England, and colleagues retrospectively collected cases from U.K. hospitals limited to patients with a diagnosis of COVID-19 and presence of pneumothorax or pneumomediastinum. Data were included for 71 patients, 60 of whom had pneumothoraces (six with pneumomediastinum) and 11 had pneumomediastinum alone.
Two of the patients with pneumomediastinum alone had distinct episodes of pneumothorax, resulting in a total of 62 pneumothoraces. The researchers observed no difference in survival at 28 days following pneumothorax or isolated pneumomediastinum (63.1 ± 6.5 percent and 53.0 ± 18.7 percent, respectively). Men had higher incidence of pneumothorax. Survival at 28 days did not differ for men versus women (62.5 ± 7.7 percent versus 68.4 ± 10.7 percent). Compared with younger patients, those aged 70 years and older had significantly lower 28-day survival (41.7 ± 13.5 percent versus 70.9 ± 6.8 percent survival).
"Although a punctured lung is a very serious condition, COVID-19 patients younger than 70 tend to respond very well to treatment," Martinelli said in a statement. "Older patients or those with abnormally acidic blood are at greater risk of death and may therefore need more specialist care."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 25, 2022